Fig. 2: Modification of the immune response by FDA-approved agents.
From: Comprehensive screening for drugs that modify radiation-induced immune responses
a Heat map showing ISRE and NF-κB activities after administering 2595 FDA-approved agents at concentrations of 10 μM. Fold-change is shown with respect to the untreated group. b ISRE and NF-κB activities after administering 233 agents associated with cancer at a concentration range of 10–0.1 μM. Fold-change is shown with respect to the untreated group. c ISRE activities after administering the drugs to non-small cell lung cancer cells irradiated at 8 Gy/4 fr. Values are expressed relative to the activity of the IR-alone (drug-free) group as 100. d Percentage of micronuclei formation after administering vinorelbine or paclitaxel with or without 8 Gy/4 fr irradiation. Error bars represent STDEV. ns, not significant, as determined by unpaired Student’s t-test between IR-alone with IR with the drug group. ISRE interferon-stimulated response element, NIR non-irradiated, IR irradiated, PEM pemetrexed, PTX paclitaxel, CDDP cisplatin, DOC docetaxel, CBDCA carboplatin, ETP etoposide, GEM gemcitabine, VNR vinorelbine, Dex dexamethasone.
